Literature DB >> 12518377

Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma.

Christopher H Crane1, John M Skibber, Barry W Feig, Jean-Nicolas Vauthey, Howard D Thames, Steve A Curley, Miguel A Rodriguez-Bigas, Robert A Wolff, Lee M Ellis, Marc E Delclos, Edward H Lin, Nora A Janjan.   

Abstract

BACKGROUND: Although controversial, some believe that preoperative chemoradiation increases the use of sphincter-preserving surgery in low rectal carcinoma patients. This article investigates the relationship between objective tumor response and sphincter preservation in low rectal carcinoma patients.
METHODS: The authors reviewed the records of 238 patients with T3 or T4 low rectal carcinoma (< or = 6 cm from the anal verge) who underwent preoperative pelvic chemoradiation (45 Gy/25 fractions/5 weeks, n = 182 or 52.5 Gy/30 fractions/5 weeks, n = 56 with continuous infusion 5-fluorouracil at 300 mg/m(2), Monday to Friday) followed by mesorectal (n = 223) or local excision (n = 15). A logistic regression analysis was used to analyze the influence of objective tumor response (defined as complete clinical response) and other prognostic factors on sphincter preservation. Because degrees of partial response could not be objectively defined retrospectively, the influence of partial response on sphincter preservation could not be evaluated.
RESULTS: Overall, 49% of patients (117 of 238) had sphincter-preserving surgery. The clinical complete response rate was 47%. Independent predictors of sphincter preservation included the year of surgery, tumor distance from the anal verge, circumferential tumor involvement, and response to chemoradiation. The sphincter preservation rate increased over the period of the study (from 28% [December 1989 to December 1992] to 44% [January 1993 to December 1996] to 67% [January 1997 to December 2000]). The difference in the rates of sphincter preservation according to response was most striking among patients with tumors 3 cm or less from the anal verge (44% vs. 22%, P = 0.01). The pelvic disease recurrence rate among patients undergoing sphincter-preserving surgery has been less than 10% since January 1993 and was not statistically different between the groups treated from January 1993 to December 1996 and from January 1997 to December 2000.
CONCLUSIONS: There has been an increase in the use of sphincter-preserving surgery without an increase in pelvic disease recurrence over the past decade. Although not necessary for sphincter preservation, clinical response to preoperative chemoradiation independently contributed to sphincter-preserving surgery, particularly in patients with low rectal tumors. Copyright 2003 American Cancer Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12518377     DOI: 10.1002/cncr.11075

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  53 in total

1.  Evaluating toxicity in neoadjuvant radio-chemotherapy of rectal cancer.

Authors:  Stefan Höcht
Journal:  Int J Colorectal Dis       Date:  2003-07-15       Impact factor: 2.571

2.  Colorectal Cancer OncoGuia.

Authors:  Paula Manchon Walsh; Josep M Borràs; Tàrsila Ferro; Josep Alfons Espinàs
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

3.  A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial.

Authors:  Julio Garcia-Aguilar; Qian Shi; Charles R Thomas; Emily Chan; Peter Cataldo; Jorge Marcet; David Medich; Alessio Pigazzi; Samuel Oommen; Mitchell C Posner
Journal:  Ann Surg Oncol       Date:  2011-07-14       Impact factor: 5.344

4.  Imunoexpression of Ki-67 and p53 in rectal cancer tissue after treatment with neoadjuvant chemoradiation.

Authors:  Nara Rosana Andrade; Celina Tizuko Fujiyama Oshima; Thiago Simão Gomes; Ricardo Artigiani Neto; Nora Manoukian Forones
Journal:  J Gastrointest Cancer       Date:  2011-03

5.  Increased spontaneous apoptosis, but not survivin expression, is associated with histomorphologic response to neoadjuvant chemoradiation in rectal cancer.

Authors:  Dermot T McDowell; Fraser M Smith; John V Reynolds; Stephen G Maher; Collette Adida; Paul Crotty; Eoin F Gaffney; Donal Hollywood; Brian Mehigan; Richard B Stephens; M J Kennedy
Journal:  Int J Colorectal Dis       Date:  2009-07-11       Impact factor: 2.571

6.  Changing operative strategy from abdominoperineal resection to sphincter preservation in T3 low rectal cancer after downstaging by neoadjuvant chemoradiation: a preliminary report.

Authors:  Khaled M Madbouly; Ahmed M Hussein
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

7.  The impact of surgical diversion before neoadjuvant therapy for rectal cancer.

Authors:  Brandon J Anderson; Elizabeth G Hill; Robert E Sweeney; Amy E Wahlquist; David T Marshall; Kevin F Staveley O'Carroll; David J Cole; Ernest Ramsay Camp
Journal:  Am Surg       Date:  2015-05       Impact factor: 0.688

Review 8.  Rectal cancer treatment: improving the picture.

Authors:  Juan A Diaz-Gonzalez; Leire Arbea; Javier Aristu
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

9.  Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy.

Authors:  Yi-Ying Lee; Chien-Feng Li; Ching-Yih Lin; Sung-Wei Lee; Ming-Jen Sheu; Li-Ching Lin; Tzu-Ju Chen; Ting-Feng Wu; Chung-Hsi Hsing
Journal:  Tumour Biol       Date:  2014-08-07

10.  Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes.

Authors:  Leonard L Gunderson; John Milburn Jessup; Daniel J Sargent; Frederick L Greene; Andrew Stewart
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.